News

Healio3y
Chocolate Touch DCB successful in head-to-head trial in femoropopliteal disease
The primary efficacy endpoint — DCB success at 12 months, defined as a composite of primary patency without clinically driven bailout stenting — was reported in 78.8% in the Chocolate Touch ...
Healio7y
DCB approved to treat lesions in dialysis fistulae - Healio
The DCB (Lutonix 035 Drug-Coated Balloon PTA Catheter) was previously approved for treatment of lesions in the superficial femoral and popliteal arteries, according to a press release issued by ...
Yahoo Finance4y
Five-year ILLUMENATE EU RCT and Pivotal study results confirm safety profile of Philips Stellarex .035” low-dose drug-coated balloon - Yahoo Finance
The five-year results for the ILLUMENATE Pivotal study also show no statistically significant difference among patients treated with the Stellarex DCB (21.2%) compared to those treated with PTA ...
Nasdaq4y
Four-year results from patient-level meta-analysis confirm safety profile of Philips Stellarex .035” low-dose drug-coated balloon - Nasdaq
Meta-analysis of two major randomized controlled trials (RCTs) show no difference in mortality between patients treated with the Philips Stellarex drug-coated balloon (DCB) and those treated with ...